Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019;124(11):1598–617.
Article CAS PubMed PubMed Central Google Scholar
Moles VM, Grafton G. Pulmonary hypertension in heart failure with preserved ejection fraction. Cardiol Clin. 2022;40(4):533–40.
Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023;329(10):827–38.
Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53(13):1119–26.
Article PubMed PubMed Central Google Scholar
Inampudi C, Silverman D, Simon MA, Leary PJ, Sharma K, Houston BA, et al. Pulmonary hypertension in the context of heart failure with preserved ejection fraction. Chest. 2021;160(6):2232–46.
Article PubMed PubMed Central Google Scholar
Vachiéry JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019;53(1):1801897. https://doi.org/10.1183/13993003.01897-2018. PMID: 30545974; PMCID: PMC6351334.
Article CAS PubMed PubMed Central Google Scholar
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879. https://doi.org/10.1183/13993003.00879-2022. PMID: 36028254.
Maron BA, Kovacs G, Vaidya A, Bhatt DL, Nishimura RA, Mak S, et al. Cardiopulmonary hemodynamics in pulmonary hypertension and heart failure: JACC review topic of the week. J Am Coll Cardiol. 2020;76(22):2671–81.
Article PubMed PubMed Central Google Scholar
Omote K, Sorimachi H, Obokata M, Reddy YNV, Verbrugge FH, Omar M, et al. Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications. Eur Heart J. 2022;43(36):3417–31.
Article PubMed PubMed Central Google Scholar
Sera F, Ohtani T, Tamaki S, Yano M, Hayashi T, Nakagawa A, et al. Pulmonary hypertension with a precapillary component in heart failure with preserved ejection fraction. Heart. 2023;109(8):626–33. https://doi.org/10.1136/heartjnl-2022-321565. PMID: 36543519.
Assad TR, Hemnes AR, Larkin EK, Glazer AM, Xu M, Wells QS, et al. Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension. J Am Coll Cardiol. 2016;68(23):2525–36.
Article PubMed PubMed Central Google Scholar
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032.
Tampakakis E, Shah SJ, Borlaug BA, Leary PJ, Patel HH, Miller WL, et al. Pulmonary effective arterial elastance as a measure of right ventricular afterload and its prognostic value in pulmonary hypertension due to left heart disease. Circ Heart Fail. 2018;11(4):e004436. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004436. PMID: 29643065; PMCID: PMC5901761.
Article PubMed PubMed Central Google Scholar
Inciardi RM, Abanda M, Shah AM, Cikes M, Claggett B, Skali H, et al. Right ventricular function and pulmonary coupling in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2023;82(6):489–99.
Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7(6):935–44.
Heywood JT, Jermyn R, Shavelle D, Abraham WT, Bhimaraj A, Bhatt K, et al. Impact of practice-based management of pulmonary artery pressures in 2000 patients implanted with the CardioMEMS sensor. Circulation. 2017;135(16):1509–17.
Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J. 2015;169(3):323–33.
Article CAS PubMed PubMed Central Google Scholar
Mentz RJ, Anstrom KJ, Eisenstein EL, Sapp S, Greene SJ, Morgan S, et al. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA. 2023;329(3):214–23.
Article CAS PubMed PubMed Central Google Scholar
Benza RL, Raina A, Abraham WT, Adamson PB, Lindenfeld J, Miller AB, et al. Pulmonary hypertension related to left heart disease: insight from a wireless implantable hemodynamic monitor. J Heart Lung Transplant. 2015;34(3):329–37.
Assmus B, Angermann CE, Alkhlout B, Asselbergs FW, Schnupp S, Brugts JJ, et al. Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension: insights from the MEMS-HF study. Eur J Heart Fail. 2022;24(12):2320–30.
Article CAS PubMed Google Scholar
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92.
Article CAS PubMed Google Scholar
Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) Trial. Circulation. 2015;131(1):34–42.
Article CAS PubMed Google Scholar
De Denus S, O’Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, et al. Spironolactone metabolites in TOPCAT-new insights into regional variation. N Engl J Med. 2017;376(17):1690–2.
Article PubMed PubMed Central Google Scholar
Safdar Z, Cho E. Effect of spironolactone use in pulmonary arterial hypertension-analysis from pivotal trial databases. Pulm Circ. 2021;11(4):20458940211045616.
Article PubMed PubMed Central Google Scholar
Maron BA, Waxman AB, Opotowsky AR, Gillies H, Blair C, Aghamohammadzadeh R, et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol. 2013;112(5):720–5.
Article CAS PubMed PubMed Central Google Scholar
Lu M, Chen LY, Gairhe S, Mazer AJ, Anderson SA, Nelson JNH, et al. Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model. Am J Physiol Lung Cell Mol Physiol. 2022;322(3):L315–32.
Article CAS PubMed PubMed Central Google Scholar
Lahm T, Hess E, Barón AE, Maddox TM, Plomondon ME, Choudhary G, et al. Renin-angiotensin-aldosterone system inhibitor use and mortality in pulmonary hypertension: insights from the veterans affairs clinical assessment reporting and tracking database. Chest. 2021;159(4):1586–97.
Article CAS PubMed Google Scholar
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.
Article CAS PubMed Google Scholar
Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.
Article CAS PubMed Google Scholar
Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–45.
Article CAS PubMed Google Scholar
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–20.
Article CAS PubMed Google Scholar
Solomon SD, Vaduganathan MBLC, Packer M, Zile M, Swedberg K, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141(5):352–61.
Clements RT, Vang A, Fernandez-Nicolas A, Kue NR, Mancini TJ, Morrison AR, et al. Treatment of pulmonary hypertension with angiotensin II receptor blocker and neprilysin inhibitor sacubitril/valsartan. Circ Heart Fail. 2019;12(11):e005819.
Article CAS PubMed PubMed Central Google Scholar
Chaumais MC, Djessas MRA, Thuillet R, Cumont A, Tu L, Hebert G, et al. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. Cardiovasc Res. 2021;117(5):1391–401.
Article CAS PubMed Google Scholar
Zhang J, Du L, Qin X, Guo X. Effect of sacubitril/valsartan on the right ventricular function and pulmonary hypertension in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of observational studies. J Am Heart Assoc
Comments (0)